Studies on Plasma Thromboxane B<sub><nobr>2</nobr></sub> Levels in Patients with Kawasaki Disease; as an Indicator of Coronary Aneurysm Formation期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Studies on Plasma Thromboxane B₂ Levels in Patients with Kawasaki Disease; as an Indicator of Coronary Aneurysm Formation

Authors:	Yasuzi Inamo

Affiliation:	Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan.

Abstract:

Keywords:	Kawasaki disease Thromboxane B2 Coronary aneurysm Kawasaki disease affects children under four years of age and is characterized by acute inflammatory disease with systemic vasculitis. Kawasaki disease is associated with a high incidence of cardiovascular complications such as thrombotic occlusion and aneurysm of the coronary arteries. Thromboxane A2 has the action of vasoconstriction, and increased platelet aggregability. Thromboxane A2 is readily metabolized to the inactive thromboxane B2 in the initial stage of Kawasaki disease. Plasma thromboxane B2 levels in normal subjects were 0.28+- 0.19 ng/ml (mean +- SD n=10). Plasma thromboxane B2 levels in patients with Kawasaki disease before treatment, were 0.33 +- 0.21 ng/ml (mean +- SD n=27). Patients with coronary aneurysm had markedly increased plasma thromboxane B2 levels (2.16+- 0.89 ng/ml n=5). Elevation of plasma thromboxane B2 levels indicates that there is the possibility of endothelial injury and aneurysm formation. Also, plasma thromboxane B2 levels immediately decreased after the start of treatment with aspirin or flurbiprofen. On the other hand, there was no significant eveidence that the production of thromboxane A2 was inhibited by steroid treatment. Therefore, the treatment with aspirin in the initial stage is more effective in preventing aneurysm formation. These results suggest that Kawasaki disease is closely associated with prostglandin metabolism including thromboxane A2.

设为首页 | 免责声明 | 关于勤云 | 加入收藏